Drug Firm Agrees to Correct Naprosyn False Advertising

By Williams, Rebecca D. | FDA Consumer, April 1992 | Go to article overview
Save to active project

Drug Firm Agrees to Correct Naprosyn False Advertising


Williams, Rebecca D., FDA Consumer


All good advertisements pitch their products in the best possible light. But when it comes to advertising drugs, FDA won't allow those ads to be colored with deception.

FDA made that point clear recently in an investigation of Syntex Laboratories of Palo Alto, Calif., which had been advertising unapproved uses for an arthritis drug. Last October, FDA and Syntex signed a consent decree requiring the firm to stop the misleading advertising and set up a $2 million account to pay for a campaign to correct the misinformation.

The action came as part of a larger FDA initiative pushing for accurate labeling in thousands of foods, drugs, and medical devices and was hailed by FDA Commissioner David Kessler, M.D., as a landmark case and "an important and innovative approach to remedying promotional abuses by drug companies."

Syntex Laboratories had advertised that its top-selling product, a prescription arthritis drug called Naprosyn, was "arthroprotective"--that is, it could prevent joint deterioration from arthritis. In fact, no clinical studies have proven that claim. Naprosyn has been approved by FDA only for treating pain, inflammation and fever in people with arthritis and other inflammatory conditions.

Syntex promoted Naprosyn's alleged arthroprotective qualities in brochures, print advertisements, video programs and advertisements, and a seminar set up to look like an impartial medical forum.

FDA first learned of these violations in 1988 through routine checks of the company's advertisements. Whenever drug companies run new ads for print, video or radio, they must also submit copies to FDA before the ads run.

FDA warned Syntex that its advertisements were in violation of the Food, Drug, and Cosmetic Act. Syntex said it would stop using the term "arthroprotective"--yet it continued to suggest in promotional activities and materials that the drug could prevent joint deterioration.

In May 1991, Syntex advertised those claims again in a promotional booklet used by its sales representatives. David Banks, a consumer safety officer with FDA's division of drug advertising and labeling in Rockville, Md., quickly saw that the booklet violated FDA rules.

"They had been told specifically and repeatedly not to make claims of this type." says Banks, "and they went ahead and did it."

Since Syntex had repeatedly ignored FDA's warnings, Banks requested an onsite inspection of the company in Palo Alto, Calif. FDA investigators also took inventory of Naprosyn stock in two Syntex warehouse to prepare for a seizure if necessary.

FDA investigators Paul Peterson and Brian Hasselbalch from the San Francisco district office began their investigation in May 1991.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Drug Firm Agrees to Correct Naprosyn False Advertising
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?